Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Taplin

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
Clinical review 134: The endocrinology of prostate cancerM E Taplin, S M Ho
American Journal of Clinical Pathology|January 1, 1986
Vitamin B12 levels and ageJ C Hitzhusen, M E Taplin, W P Stephenson, et al.
Seminars in Oncology|December 22, 1999
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780D Savarese, M E Taplin, S Halabi, et al.
Prostate Cancer and Prostatic Diseases|August 10, 2016
Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancerR R McKay, L Werner, M Fiorillo, et al.
Archives of Internal Medicine|May 1, 1988
Presumptive evidence for Blastocystis hominis as a cause of colitisA R Russo, S L Stone, M E Taplin, et al.
Immunology|March 1, 1996
Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expressionM E Taplin, M E Frantz, C Canning, et al.
Seminars in Oncology|October 31, 2001
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancerM E Taplin, G J Bubley, B Rajeshkumar, et al.
Cancer Research|June 11, 1999
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonistM E Taplin, G J Bubley, Y J Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Functional characterization of mutant androgen receptors from androgen-independent prostate cancerM A Fenton, T D Shuster, A M Fertig, et al.
The American Journal of Pathology|July 5, 2001
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinomaI Leav, K M Lau, J Y Adams, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
Clinical review 134: The endocrinology of prostate cancerM E Taplin, S M Ho
American Journal of Clinical Pathology|January 1, 1986
Vitamin B12 levels and ageJ C Hitzhusen, M E Taplin, W P Stephenson, et al.
Seminars in Oncology|December 22, 1999
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780D Savarese, M E Taplin, S Halabi, et al.
Prostate Cancer and Prostatic Diseases|August 10, 2016
Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancerR R McKay, L Werner, M Fiorillo, et al.
Archives of Internal Medicine|May 1, 1988
Presumptive evidence for Blastocystis hominis as a cause of colitisA R Russo, S L Stone, M E Taplin, et al.
Immunology|March 1, 1996
Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expressionM E Taplin, M E Frantz, C Canning, et al.
Seminars in Oncology|October 31, 2001
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancerM E Taplin, G J Bubley, B Rajeshkumar, et al.
Cancer Research|June 11, 1999
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonistM E Taplin, G J Bubley, Y J Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Functional characterization of mutant androgen receptors from androgen-independent prostate cancerM A Fenton, T D Shuster, A M Fertig, et al.
The American Journal of Pathology|July 5, 2001
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinomaI Leav, K M Lau, J Y Adams, et al.
Pageof 2